(Q46276281)

English

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

scientific article published in October 2008

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

multiple sclerosis

0 references

0 references

relapsing-remitting multiple sclerosis

0 references

1 reference

based on heuristic

inferred from title

1

object named as

Ludwig Kappos

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

2

object named as

Ralf Gold

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

David H. Miller

3

object named as

David H Miller

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

author name string

David G Macmanus

4

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

Eva Havrdova

5

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

Volker Limmroth

6

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

Chris H Polman

7

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

Klaus Schmierer

8

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

Tarek A Yousry

9

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

Minhua Yang

10

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

Mefkûre Eraksoy

11

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

Eva Meluzinova

12

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

Ivan Rektor

13

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

Katherine T Dawson

14

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

Alfred W Sandrock

15

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

Gilmore N O'Neill

16

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

BG-12 Phase IIb Study Investigators

17

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

language of work or name

0 references

publication date

1 October 2008

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

372

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

9648

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

1463-1472

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Acetylcarnitine induces heme oxygenase in rat astrocytes and protects against oxidative stress: involvement of the transcription factor Nrf2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Stabilization of Nrf2 by tBHQ confers protection against oxidative stress-induced cell death in human neural stem cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophilic [correction of electrophillic] phase II inducers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Fibroblast growth factor-1 induces heme oxygenase-1 via nuclear factor erythroid 2-related factor 2 (Nrf2) in spinal cord astrocytes: consequences for motor neuron survival.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Promoting remyelination in multiple sclerosis by endogenous adult neural stem/precursor cells: defining cellular targets.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Vacuolar leukoencephalopathy with widespread astrogliosis in mice lacking transcription factor Nrf2

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Detoxication enzyme inducers modify cytokine production in rat mixed glial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Dimethylfumarate inhibits tumor-necrosis-factor-induced CD62E expression in an NF-kappa B-dependent manner

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Sample size estimations for MRI-monitored trials of MS comparing new vs standard treatments.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationship between inflammatory lesions and cerebral atrophy in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Reactive oxygen species are required for the phagocytosis of myelin by macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of reactive oxygen species in the pathogenesis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Measurement of low-molecular-weight antioxidants, uric acid, tyrosine and tryptophan in plaques and white matter from patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Bilirubin as a potent antioxidant suppresses experimental autoimmune encephalomyelitis: implications for the role of oxidative stress in the development of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961619-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(08)61619-0

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18970976

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46276281&oldid=2116008429"